Santen Pharmaceutical Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and commercialization of pharmaceuticals and medical devices. Headquartered in Osaka, Japan, its core focus lies in ophthalmology. The company boasts a robust pipeline of treatments for various eye conditions. For glaucoma and ocular hypertension, its offerings include DE-111 and DE-130A, both in Phase III clinical trials; DE-117, available in Japan; DE-126, currently in Phase IIb development; and DE-128, which is marketed in Europe and undergoing Phase II/III trials in the United States. Santen also addresses other ophthalmic conditions: DE-114A for allergic conjunctivitis, DE-076C for vernal keratoconjunctivitis, and DE-109, which is in Phase III development for uveitis. Its pipeline further includes treatments for myopia, such as DE-127 (in Phase II/III in Japan and Phase III across Asia) and STN1013400 (in Phase I). Additionally, DE-089C has successfully completed Phase III clinical trials for dry eye treatment. Beyond prescription medications, Santen also provides over-the-counter (OTC) pharmaceutical products. Founded in Osaka, Japan, in 1890, the company adopted its current name, Santen Pharmaceutical Co., Ltd., in 1958, having previously operated as Santendo Pharmaceutical Co., Ltd.
—
Santen Pharmaceutical Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and commercialization of pharmaceuticals and medical devices. Headquartered in Osaka, Japan, its core focus lies in ophthalmology. The company boasts a robust pipeline of treatments for various eye conditions. For glaucoma and ocular hypertension, its offerings include DE-111 and DE-130A, both in Phase III clinical trials; DE-117, available in Japan; DE-126, currently in Phase IIb development; and DE-128, which is marketed in Europe and undergoing Phase II/III trials in the United States. Santen also addresses other ophthalmic conditions: DE-114A for allergic conjunctivitis, DE-076C for vernal keratoconjunctivitis, and DE-109, which is in Phase III development for uveitis. Its pipeline further includes treatments for myopia, such as DE-127 (in Phase II/III in Japan and Phase III across Asia) and STN1013400 (in Phase I). Additionally, DE-089C has successfully completed Phase III clinical trials for dry eye treatment. Beyond prescription medications, Santen also provides over-the-counter (OTC) pharmaceutical products. Founded in Osaka, Japan, in 1890, the company adopted its current name, Santen Pharmaceutical Co., Ltd., in 1958, having previously operated as Santendo Pharmaceutical Co., Ltd.
—
Daily adjusted close
Santen Pharmaceutical Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and commercialization of pharmaceuticals and medical devices. Headquartered in Osaka, Japan, its core focus lies in ophthalmology. The company boasts a robust pipeline of treatments for various eye conditions. For glaucoma and ocular hypertension, its offerings include DE-111 and DE-130A, both in Phase III clinical trials; DE-117, available in Japan; DE-126, currently in Phase IIb development; and DE-128, which is marketed in Europe and undergoing Phase II/III trials in the United States. Santen also addresses other ophthalmic conditions: DE-114A for allergic conjunctivitis, DE-076C for vernal keratoconjunctivitis, and DE-109, which is in Phase III development for uveitis. Its pipeline further includes treatments for myopia, such as DE-127 (in Phase II/III in Japan and Phase III across Asia) and STN1013400 (in Phase I). Additionally, DE-089C has successfully completed Phase III clinical trials for dry eye treatment. Beyond prescription medications, Santen also provides over-the-counter (OTC) pharmaceutical products. Founded in Osaka, Japan, in 1890, the company adopted its current name, Santen Pharmaceutical Co., Ltd., in 1958, having previously operated as Santendo Pharmaceutical Co., Ltd.